TITLE

11. Pharmacy Benefit Management Plans

PUB. DATE
January 2006
SOURCE
Employee Benefit News;Benefits 2006 Sourcebook, Vol. 19, p68
SOURCE TYPE
Periodical
DOC. TYPE
Directory
ABSTRACT
This section presents a directory of pharmacy benefit management plans providers in the U.S. Companies that are listed include, AcitvaRx Inc., AmeriScript Inc., Corporate Benefits Plus, Managed Pharmacy Benefits Inc., and Novartis Pharmaceuticals Corp.
ACCESSION #
19417281

 

Related Articles

  • Directory of prescription benefit managers.  // Business Insurance;12/29/2003, Vol. 37 Issue 52, p144 

    This article presents a directory of prescription benefit managers, published in the December 29, 2003, issue of the periodical "Business Insurance." Some of the firms listed are Ohio-based AmeriScript Inc., Illinois-based Caremark Rx Inc. and Missouri-based Express Scripts Inc. Directory of...

  • Novartis launches new U.S. facility.  // Drug Topics;10/6/97, Vol. 141 Issue 19, p8 

    States that Novartis Pharmaceuticals has opened a million dollar manufacturing plant in Suffern, New York. What the company will manufacture; Exact cost of the manufacturing plant.

  • Implementation of and experiences with new automation. Mahmud, Ifte; Kim, David // Journal of Automated Methods & Management in Chemistry;Nov2000, Vol. 22 Issue 6, p199 

    In an environment where cost, timeliness, and quality drives the business, it is essential to look for answers in technology where these challenges can be met. In the Novartis Pharmaceutical Quality Assurance Department, automation and robotics have become just the tools to meet these...

  • A promising antiepileptic drug gains approval for market. Magill-Lewis, Jillene // Drug Topics;2/7/2000, Vol. 144 Issue 3, p30 

    Provides information on Trileptal or oxcarbazepine, an antiepileptic drug from Novartis Pharmaceuticals Corp. Efficacy and safety of oxcarbazepine; Side effects of oxcarbazepine; Average wholesale price for a month's supply of oxcarbazepine oral tablets.

  • Alzheimer's patients now have a topical option.  // Drug Topics;7/23/2007, Vol. 151 Issue 14, p6 

    The article evaluates Novartis Pharmaceuticals Corp.'s Exelon® Patch Rivastigmine transdermal system for the treatment of Alzheimer's disease.

  • Correction.  // Advertising Age;10/27/1997, Vol. 68 Issue 43, p36 

    The article presents a correction to the article "Novartis breaks $12 million effort for new Tavist Sinus," in the October 20, 1997 issue.

  • U.S. business restructured by Novartis.  // Chain Drug Review;2/13/2012, Vol. 34 Issue 3, p11 

    The article reports that Novartis Pharmaceuticals Corp. is revamping its business operations in the U.S.

  • First gallstone prevention medication.  // Modern Medicine;Jul97, Vol. 65 Issue 7, p43 

    Reports on Novartis Pharmaceuticals Corp.'s marketing of a drug called Ursodiol USP for use in the prevention of gallstone formation in obese patients who are experiencing rapid weight loss. Recommended dosage; Side effects; Indications.

  • DRUG INFORMATION.  // American Journal of Hematology/Oncology;Oct2009, Vol. 8 Issue 10, p512 

    The article evaluates the drug Gleeves with generic name Imatinib from Novartis Pharmaceuticals Corp.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics